+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Inhibitors Market: Industry Trends and Global Forecasts, till 2030- Product Image
Immune Checkpoint Inhibitors Market: Industry Trends and Global Forecasts, till 2030- Product Image
New

Immune Checkpoint Inhibitors Market: Industry Trends and Global Forecasts, till 2030

  • PDF Icon

    Report

  • 318 Pages
  • March 2026
  • Region: Global
  • Roots Analysis
  • ID: 6230122
Description Jump to:
The immune checkpoint inhibitors market is estimated to be worth USD 62 billion in the current year and reach USD 246 billion in 2035, growing at a CAGR of 14.7% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Immune Checkpoint Inhibitors Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Immune Checkpoint Proteins

  • PD-1
  • PD-L1
  • CTLA-4
  • Others

Target Disease Indication

  • Lung Cancer
  • Breast Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Melanoma
  • Hodgkin Lymphoma
  • Others

Type of Therapeutic Modality

  • Antibody Fragments
  • Monoclonal Antibodies
  • Small Molecules
  • Other Modalities

Route of Administration

  • Intravenous
  • Subcutaneous
  • Intracellular
  • Others

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • Latin America

IMMUNE CHECKPOINT INHIBITORS MARKET: GROWTH AND TRENDS

Cancer is recognized as a major cause of mortality globally, responsible for 0.6 million fatalities in 2019, in the US alone. The World Health Organization projects that the global incidence of new cancer cases will increase by 70% in the next 20 years. Traditional treatment methods, including chemotherapy, surgical procedures, and radiation therapy, remain the established standard of care. Nonetheless, their effectiveness is significantly constrained, particularly in the treatment of advanced-stage cancers. Further, the non-specific and extremely toxic characteristics of chemotherapy and radiation therapy are recognized to considerably affect the quality of life of individuals.

Numerous targeted cancer treatments are currently available in the market, in addition to the therapies under development. Among these, immune checkpoint therapies have demonstrated significant potential as effective and powerful treatment alternatives, capable of hindering tumor cells from escaping immune detection. In 2011, Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody from Bristol-Myers Squibb, was the first immune checkpoint inhibitor approved by the FDA for treating metastatic melanoma. Yervoy®, together with other early immune checkpoint inhibitors (focusing on PD-1/PD-L1 and CTLA-4), demonstrated potential to significantly extend the lives of individuals with advanced tumors. Nonetheless, despite the effectiveness of PD 1 / PD-L1 immune checkpoint inhibitors, a significant level of resistance to treatment was observed in some patient groups, which hindered the therapeutic effectiveness of this relatively new category of treatments.

Throughout the years, considerable advancements have happened in immune checkpoint modulation research, uncovering various inhibitory (LAG-3, TIM-3, TIGIT, VISTA, and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB, and CD40) that are currently being utilized for the creation of next-generation immune checkpoint-focused therapies. Additionally, clinical research on combinatorial immune checkpoint blockade and co-stimulation, which includes both newly discovered checkpoints and established immune checkpoint inhibitor therapies, has shown the ability to enhance therapeutic advantages. It is important to note that these molecules have also demonstrated the ability to regulate immune tolerance and to prevent or treat autoimmune diseases. Consequently, supported by encouraging clinical outcomes and increasing applicability of therapies under late-stage investigation, the immune checkpoint inhibitors and stimulators market is expected to experience significant growth throughout the forecast period.

IMMUNE CHECKPOINT INHIBITORS MARKET: KEY INSIGHTS

The report delves into the current state of global immune checkpoint inhibitors market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • The success of any clinical research study is heavily dependent on its endpoints and outcome measures used, which should be well defined and reliable, readily measurable, sensitive, and clinically meaningful.
  • Since 2000, over 3,600 clinical trials focused on the evaluation of PD-1 / PD-L1 targeting immune checkpoint inhibitors have been registered across the world.
  • Presently, there are over 450 scientific articles showcasing the results of completed and ongoing clinical studies; most of these publications are featured in peer-reviewed journals having impact factors ranging from 1 to 20.
  • The report features detailed summaries of the key takeaways from 85+ clinical research publications, which showcase and discuss the results of both approved and under development PD-1 / PD-L1 targeting drugs.

  • Phase I trials captured in the report feature a variety of new molecular entities designed for PD-1 signaling blockade for the treatment of various types of tumors, including metastatic cancers.
  • Phase II trials are primarily focused on how safe a treatment is and how well it works; typically, these studies are conducted for specific indications and may involve combinations of drugs / therapies.
  • Phase III of clinical research is an elaborate, multicenter study, involving patients shortlisted based on established selection criteria from across the world; understanding the side effects profile is a key objective.

  • The importance of trial design is paramount; it not only serves to optimize, and economize the process, but also helps define critical objectives (such as superiority, non-inferiority, or equivalence) directing the course of research.
  • In the contemporary clinical research scenario, multiple new PD-1 / PD-L1 inhibitors are being evaluated, and several of the approved products are also being investigated in combination with other product classes.
  • Considering the target-specific nature of these therapies, the expression of PD-L1 is considered an important criterion while designing trials of immune checkpoint blockade-directed treatment options.
  • A number of trials have been designed to objectively determine whether the new therapeutic agent, or combination regimen, has sufficient biological activity in order to warrant further research.

  • The focus of late phase clinical studies is usually on assessing long term therapy related outcomes and affiliated toxicities, across different groups of patients.
  • Although multiple PD-1 / PD-L1 targeting drugs are already in the market, several new biological drug candidates are under evaluation and are likely to enter the market in the foreseen future.

Example Players in the Immune Checkpoint Inhibitors Market

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Incyte
  • Novartis
  • Trillium Therapeutics

IMMUNE CHECKPOINT INHIBITORS MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global immune checkpoint inhibitors market, focusing on key market segments, including [A] key immune checkpoint targets, [B] target indication, [C] mechanism of action, [D] therapeutic modalities used, [H] type of therapy, [I] route of administration, and [J] key geographical regions
  • Market Landscape: A comprehensive evaluation of marketed / pipeline molecules, considering various parameters, such as [A] phase of development of lead candidates, [B] target immune checkpoints, [C] mechanism of action, [D] type of therapeutic modality used, [E] route of administration and [F] target disease indication, [G] target therapeutic area and [H] type of therapy.
  • Company Profiles: In-depth profiles of next generation immune checkpoint modulators, focusing on [A] company overview, [B] financial information (if available), [C] product portfolio, and [E] recent developments and an informed future outlook.
  • Grants Analysis: An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, based on parameters, such as [A] year of grant award, [B] amount awarded, [C] administration institute center, [D] funding institute center, [E] support period, [F] type of grant application, [G] purpose of grant award, [H] grant mechanism, [I] popular target immune checkpoints, [J] responsible study section, [K] focus area, [L] prominent program officers, and [M] type of recipient organizations.
  • Partnerships and Collaborations: A comprehensive analysis of various collaborations and partnerships that have been inked amongst stakeholders in this domain, based on [A] year of partnership, [B] type of partnership and [C] regional activity.
  • Target Competitiveness Analysis: A detailed analysis of the biological targets, taking into consideration the number of lead molecules based on a particular target, [A] phase of development of candidate therapies, [B] number of grants and [C] number of publications, a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
  • Big Pharma Players: A detailed analysis of the big pharma players, based on parameters, such as [A] number of therapies under development, [B] target disease indications, [C] partnership activity, and [D] target portfolio.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs Covering All Analytical Modules
  • Up to 15% Complimentary Content Customization
  • In-Depth Report Walkthrough with the Research Team
  • Complimentary Report Update if the Report is 6+ Months Old

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. Immune Checkpoint Modulators
3.5. First Generation Immune Checkpoint Modulators
3.6. Next Generation Immune Checkpoint Modulators
3.6.1. Types of Next Generation Immune Checkpoint Modulators
3.7. Challenges-related to Immune Checkpoint Modulation-based Therapy
3.8. Future Perspectives
4. CURRENT MARKET LANDSCAPE: MARKETED AND DEVELOPMENT PIPELINE
4.1. Chapter Overview
4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Immune Checkpoint
4.3.3. Analysis by Mechanism of Action
4.3.4. Analysis by Therapeutic Modality
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Therapeutic Area
4.3.8. Analysis by Popular Oncological Indication(s) and Popular Target Immune Checkpoint
4.3.9. Analysis by Popular Non-Oncological Indication(s) and Popular Target Immune Checkpoint
4.3.10. Analysis by Popular Disease Indication(s) and Popular Target Immune Checkpoint in Highest Phase of Development
4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies
4.4.4. Popular Targets: Distribution by Number of Developers
4.4.5 World Map Representation: Analysis by Geography
5. MARKET LANDSCAPE: THERAPIES TARGETING CD47
5.1. Chapter Overview
5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies
5.3. Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Therapeutic Modality
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Target Disease Indication
5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size and Geographical Location
5.4.3. Leading Developers: Analysis by Number of Therapies
5.4.4. World Map Representation: Analysis by Geography
6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB
6.1. Chapter Overview
6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies
6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies
6.3.1. Analysis by Phase of Development
6.3.2. Analysis by Therapeutic Modality
6.3.3. Analysis by Route of Administration
6.3.4. Analysis by Target Disease Indication
6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size and Geographical Location
6.4.3. Leading Developers: Analysis by Number of Therapies
6.4.4. World Map Representation: Analysis by Geography
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Players: Analysis by Number of Registered Trials
7.3.8. Word Cloud: Key Focus Areas
7.3.9. Analysis by Target Immune Checkpoint
7.3.10. Analysis by Target Therapeutic Area
7.3.11. Popular Indications: Analysis by Number of Registered Trials
7.3.12. Popular Interventions: Analysis by Number of Registered Trials
7.3.13. Geographical Analysis by Number of Registered Trials
7.3.14. Geographical Analysis by Number of Patients Enrolled
8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS
8.1. Chapter Overview
8.2. Bristol-Myers Squibb
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. GlaxoSmithKline
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Incyte
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook
8.4. Novartis
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Trillium Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.5.4. Recent Developments and Future Outlook
9. ACADEMIC GRANTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Administering Institute Center
9.3.4. Analysis by Funding Institute Center
9.3.5. Analysis by Support Period
9.3.6. Analysis by Funding Institute Center and Support Period
9.3.7. Analysis by Type of Grant Application
9.3.8. Analysis by Purpose of Grant Award
9.3.9. Analysis by Grant Mechanism
9.3.10. Word Cloud: Emerging Focus Areas
9.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants
9.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints
9.3.13. Analysis by Study Section Involved
9.3.14. Popular NIH Departments: Analysis by Number of Grants
9.3.15. Analysis by Types of Recipient Organizations
9.3.16. Popular Recipient Organizations: Analysis by Number of Grants
9.3.17. Prominent Program Officers: Analysis by Number of Grants
9.3.18. Regional Analysis of Recipient Organizations
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Number of Partnership and Target Immune Checkpoint
10.3.4. Analysis by Year of Partnership and Type of Partner
10.3.5. Analysis by Type of Partnership and Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.4. Regional Analysis
10.4.1. Intercontinental and Intracontinental Agreements
11. TARGET COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Key Parameters
11.4. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators
11.3.1. Four-Dimensional Bubble Analysis
11.3.2 Five-Dimensional Spider Web Analysis
12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Big Pharma Initiatives Focused on Next Generation Immune Checkpoint
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Number of Targets
12.2.3. Analysis by Product Development Strategy
12.2.4. Analysis by Target Immune Checkpoint
12.2.5. Grid Representation: Analysis by Product Development Strategy and Target Immune Checkpoint
12.2.6. Analysis by Type of Intervention
12.3. Analysis by Target Disease Indication(s)
12.3.1. Heat Map: Big Pharma Initiatives Focused on Oncological Indications
12.3.2. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, Till 2030
13.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Individual Product Sales Forecasts
13.4.1. DARZALEX® (Janssen Pharmaceuticals)
13.4.1.1. Target Patient Population
13.4.1.2. Sales Forecast
13.4.2. SAR650984 (Sanofi)
13.4.2.1. Target Patient Population
13.4.2.2. Sales Forecast
13.4.3. RRx-001 (EpicentRx)
13.4.3.1. Target Patient Population
13.4.3.2. Sales Forecast
13.4.4. GSK3359609 (GlaxoSmithKline)
13.4.4.1. Target Patient Population
13.4.4.2. Sales Forecast
13.4.5. Omburtamab (Y-mAbs Therapeutics)
13.4.5.1. Target Patient Population
13.4.5.2. Sales Forecast
13.6.7. APXOO5M (Apogenix)
13.6.7.1. Target Patient Population
13.6.7.2. Sales Forecast
13.7.8. BI 655064 (Boehringer Ingelheim)
13.7.1. Target Patient Population
13.4.7.2. Sales Forecast
13.4.8. BMS-986015 (Bristol-Myers Squibb)
13.4.8.1. Target Patient Population
13.4.8.2. Sales Forecast
13.4.9. CFZ533 (Novartis)
13.4.9.1. Target Patient Population
13.4.9.2. Sales Forecast
13.4.10. GBR 830 (Glenmark)
13.4.10.1. Target Patient Population
13.4.10.2. Sales Forecast
13.4.11. KHK4083 (Kyowa Kirin)
13.4.11.1. Target Patient Population
13.4.11.2. Sales Forecast
13.12.13. LAG525 (Novartis)
13.12.13.1. Target Patient Population
13.12.13.2. Sales Forecast
13.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region
13.5.1. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in US, Till 2030
13.5.2. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, Till 2030
13.5.3. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, Till 2030
13.5.4. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, Till 2030
13.5.5. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy Till 2030
13.5.6. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, Till 2030
13.5.7. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, Till 2030
13.5.8. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, Till 2030
13.5.9. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, Till 2030
13.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area
13.6.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Indications, Till 2030
13.6.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-oncological Indications, Till 2030
13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication
13.7.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, Till 2030
13.7.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, Till 2030
13.7.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, Till 2030
13.7.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, Till 2030
13.7.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, Till 2030
13.7.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, Till 2030
13.7.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, Till 2030
13.7.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, Till 2030
13.7.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, Till 2030
13.7.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, Till 2030
13.7.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren’s Syndrome, Till 2030
13.7.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative Colitis, Till 2030
13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint
13.8.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, Till 2030
13.8.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, Till 2030
13.8.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, Till 2030
13.8.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, Till 2030
13.8.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, Till 2030
13.8.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, Till 2030
13.8.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, Till 2030
13.8.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, Till 2030
13.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action
13.9.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, Till 2030
13.9.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, Till 2030
13.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality
13.10.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, Till 2030
13.10.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecules, Till 2030
13.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy
13.11.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, Till 2030
13.11.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, Till 2030
13.11.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, Till 2030
13.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration
13.12.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, Till 2030
13.12.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, Till 2030
13.12.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, Till 2030
14. CONCLUDING REMARKS
14.1. Chapter Overview
14.2. Key Takeaways
15. EXECUTIVE INSIGHTS16. APPENDIX 1: TABULATED DATA17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1. Executive Summary: Current Market Landscape of Automated Pipetting Systems
Figure 2.2. Executive Summary: Current Market Landscape of Automated Microplate Washers
Figure 2.3. Executive Summary: Partnerships and Collaborations
Figure 2.4. Executive Summary: Patent Analysis
Figure 2.5. Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1. Manual versus Automated Liquid Handling
Figure 3.2. Working Mechanism of Automated Pipetting Systems
Figure 3.3. Advantages of Automated Pipetting Systems
Figure 3.4. Features of an Ideal Automated Microplate Washer
Figure 3.5. Applications of Automated Liquid Handling Systems
Figure 4.1. Automated Pipetting Systems: Distribution by Type of Technology
Figure 4.2. Automated Pipetting Systems: Distribution by Pipetting Technology
Figure 4.3. Automated Pipetting Systems: Distribution by Certification(s)
Figure 4.4. Automated Pipetting Systems: Distribution by Type of Instrument(s) by Assembly
Figure 4.5. Automated Pipetting Systems: Distribution by Pipetting Head Option(s)
Figure 4.6. Automated Pipetting Systems: Distribution of Weight of Automated Pipetting Systems (in Kg)
Figure 4.7. Automated Pipetting Systems: Distribution by Compatible Labware
Figure 4.8. Automated Pipetting Systems: Distribution by Application Area(s)
Figure 4.9. Automated Pipetting Systems: Distribution by Application(s)
Figure 4.10. Automated Pipetting Systems: Distribution by Additional Feature (s)
Figure 4.11. Automated Pipetting Systems: Distribution by End User(s)
Figure 4.12. Automated Pipetting System Providers: Distribution by Year of Establishment
Figure 4.13. Automated Pipetting System Providers: Distribution by Company Size
Figure 4.14. Automated Pipetting System Providers: Distribution by Location of Headquarters (Region-wise)
Figure 4.15. Automated Pipetting System Providers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 4.16. Automated Pipetting System Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.17. Most Active Players: Distribution by Number of Automated Pipetting Systems Manufactured
Figure 5.1. Company Competitiveness Analysis: Automated Pipetting System Providers based in North America (Peer Group I)
Figure 5.2. Company Competitiveness Analysis: Automated Pipetting System Providers based in Europe (Peer Group II)
Figure 5.3. Company Competitiveness Analysis: Automated Pipetting System Providers based in Asia-Pacific and Rest of the World (Peer Group III)
Figure 6.1. Beckman Coulter Life Sciences: Annual Revenues, Since 2018 (USD Billion)
Figure 6.2. Eppendorf: Annual Revenues, Since 2018 (USD Billion)
Figure 7.1. Automated Microplate Washers: Distribution by Type of Instrument(s) by Assembly
Figure 7.2. Automated Microplate Washers: Distribution by Compatible Microplate(s)
Figure 7.3. Automated Microplate Washers: Distribution by Weight of Automated Microplate Washer (in Kg)
Figure 7.4. Automated Microplate Washers: Distribution by Compatible Labware
Figure 7.5. Automated Microplate Washers: Distribution by Application Area(s)
Figure 7.6. Automated Microplate Washers: Distribution by Application(s)
Figure 7.7. Automated Microplate Washers: Distribution by End User(s)
Figure 7.8. Automated Microplate Washer Providers: Distribution by Year of Establishment
Figure 7.9. Automated Microplate Washer Providers: Distribution by Company Size
Figure 7.10. Automated Microplate Washer Providers: Distribution by Location of Headquarters (Region-wise)
Figure 7.11. Automated Microplate Washer Providers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 7.12. Automated Microplate Washer Providers: Distribution by Location Headquarters (Country-wise)
Figure 7.13. Most Active Players: Distribution by Number of Compatible Software
Figure 7.14. Most Active Players: Distribution by Number of Automated Microplate Washers Manufactured
Figure 8.1. Company Competitiveness Analysis: Automated Microplate Washer Providers based in North America (Peer Group I)
Figure 8.2. Company Competitiveness Analysis: Automated Microplate Washer Providers based in Europe (Peer Group II)
Figure 8.3. Company Competitiveness Analysis: Automated Microplate Washer Providers based in Asia-Pacific and Rest of the World (Peer Group III)
Figure 9.1. Agilent Technologies: Annual Revenues, Since 2018 (USD Billion)
Figure 9.2. Tecan: Annual Revenues, Since 2018 (CHF Million)
Figure 9.3. Thermo Fisher Scientific: Annual Revenues, Since 2018 (USD Billion)
Figure 10.1. Partnerships and Collaborations: Distribution by Year of Partnership, Since 2018
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2018
Figure 10.4. Partnerships and Collaborations: Distribution by Type of Automated Liquid Handling System(s)
Figure 10.5. Partnerships and Collaborations: Distribution by Product and Type of Partnership
Figure 10.6. Most Popular Products: Distribution by Number of Partnerships
Figure 10.7. Most Active Players: Distribution by Type of Partnership
Figure 10.8. Partnerships and Collaborations: Local and International Agreements
Figure 10.9. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 11.1. Patent Analysis: Distribution by Type of Patent
Figure 11.2. Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2017
Figure 11.3. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2017
Figure 11.4. Patent Analysis: Distribution by Geography
Figure 11.5. Patent Analysis: Distribution by CPC Sections
Figure 11.6. Word Cloud Analysis: Emerging Focus Areas
Figure 11.7. Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Since 2017
Figure 11.8. Leading Industry Players: Distribution by Number of Patents
Figure 11.9. Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10. Leading Individual Assignees: Distribution by Number of Patents
Figure 11.11. Leading Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 11.12. Patent Analysis: Distribution by Patent Age
Figure 11.13. Automated Liquid Handling Systems: Patent Valuation Analysis
Figure 12.1. Global Automated Liquid Handling Systems Market, Till 2035
Figure 12.2. Automated Liquid Handling Systems Market: Distribution by Type of Automated Liquid Handling System
Figure 12.3. Automated Pipetting Systems Market: Till 2035
Figure 12.4. Automated Pipetting Systems Market: Distribution by Pipetting Technology
Figure 12.5. Automated Pipetting Systems Market for Contact Technology, Till 2035
Figure 12.6. Automated Pipetting Systems Market for Air Displacement Technology, Till 2035
Figure 12.7. Automated Pipetting Systems Market for Piston / Positive Displacement Technology, Till 2035
Figure 12.8. Automated Pipetting Systems Market for Acoustic Technology, Till 2035
Figure 12.9. Automated Pipetting Systems Market for Free-jet Technology, Till 2035
Figure 12.10. Automated Pipetting Systems Market: Distribution by Modality
Figure 12.11. Automated Pipetting Systems Market for Fixed Tips, Till 2035
Figure 12.12. Automated Pipetting Systems Market for Disposable Tips, Till 2035
Figure 12.13. Automated Pipetting Systems Market: Distribution by Type of Instrument
Figure 12.14. Automated Pipetting Systems Market for Standalone, Till 2035
Figure 12.15. Automated Pipetting Systems Market for Individual Benchtop Workstation, Till 2035
Figure 12.16. Automated Pipetting Systems Market for Multi Instrument System, Till 2035
Figure 12.17. Automated Pipetting Systems Market for Others, Till 2035
Figure 12.18. Automated Pipetting Systems Market: Distribution by Application
Figure 12.19. Automated Pipetting Systems Market for Serial Dilution, Till 2035
Figure 12.20. Automated Pipetting Systems Market for Plate Replication, Till 2035
Figure 12.21. Automated Pipetting Systems Market for PCR / qPCR Setup, Till 2035
Figure 12.22. Automated Pipetting Systems Market for Plate Reformatting, Till 2035
Figure 12.23. Automated Pipetting Systems Market for High-throughput Screening, Till 2035
Figure 12.24. Automated Pipetting Systems Market for Whole Genome Amplification, Till 2035
Figure 12.25. Automated Pipetting Systems Market for Cell Culture, Till 2035
Figure 12.26. Automated Pipetting Systems Market for Other Applications, Till 2035
Figure 12.27. Automated Pipetting Systems Market: Distribution by End User
Figure 12.28. Automated Pipetting Systems Market for Biotechnology and Pharmaceutical Companies, Till 2035
Figure 12.29. Automated Pipetting Systems Market for Academic and Government Research Institutes, Till 2035
Figure 12.30. Automated Pipetting Systems Market for Hospitals and Diagnostic Centers, Till 2035
Figure 12.31. Automated Pipetting Systems Market for Other End Users, Till 2035
Figure 12.32. Automated Pipetting Systems Market: Distribution by Key Geographical Regions
Figure 12.33. Automated Pipetting Systems Market in North America, Till 2035
Figure 12.34. Automated Pipetting Systems Market in Europe, Till 2035
Figure 12.35. Automated Pipetting Systems Market in Asia-Pacific, Till 2035
Figure 12.36. Automated Pipetting Systems Market in Middle East and North Africa, Till 2035
Figure 12.37. Automated Pipetting Systems Market in Latin America, Till 2035
Figure 12.38. Automated Microplate Washers Market: Till 2035
Figure 12.39. Automated Microplate Washers Market: Distribution by Washing Technology
Figure 12.40. Automated Microplate Washers Market for Ultrasonic Technology
Figure 12.41. Automated Microplate Washers Market for Acoustic Technology
Figure 12.42. Automated Microplate Washers Market for Centrifugal Technology
Figure 12.43. Automated Microplate Washers Market: Distribution by Application
Figure 12.44. Automated Microplate Washers Market for ELISA, Till 2035
Figure 12.45. Automated Microplate Washers Market for Cell-based Assays, Till 2035
Figure 12.46. Automated Microplate Washers Market for Bead Washing, Till 2035
Figure 12.47. Automated Microplate Washers Market for Other Applications, Till 2035
Figure 12.48. Automated Microplate Washers Market: Distribution by End User
Figure 12.49. Automated Microplate Washers Market for Biotechnology and Pharmaceutical Companies, Till 2035
Figure 12.50. Automated Microplate Washers Market for Academic and Government Research Institutes, Till 2035
Figure 12.51. Automated Microplate Washers Market for Hospitals and Diagnostic Centers, Till 2035
Figure 12.52. Automated Microplate Washers Market for Other End Users, Till 2035
Figure 12.53. Automated Microplate Washers Market: Distribution by Key Geographical Regions
Figure 12.54. Automated Microplate Washers Market in North America, Till 2035
Figure 12.55. Automated Microplate Washers Market in Europe, Till 2035
Figure 12.56. Automated Microplate Washers Market in Asia-Pacific, Till 2035
Figure 12.57. Automated Microplate Washers Market in Middle East and North Africa, Till 2035
Figure 12.58. Automated Microplate Washers Market in Latin America, Till 2035
Figure 13.1. Automated Liquid Handling Systems: SWOT Analysis
Figure 13.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 14.1. Concluding Remarks: Current Market Landscape of Automated Pipetting Systems
Figure 14.2. Concluding Remarks: Current Market Landscape of Automated Microplate Washers
Figure 14.3. Concluding Remarks: Partnerships and Collaborations
Figure 14.4. Concluding Remarks: Patent Analysis
Figure 14.5. Concluding Remarks: Market Sizing and Opportunity Analysis
LIST OF TABLES
Table 3.1 Manual, Semi-automated and Automated Pipetting Systems
Table 4.1 Automated Pipetting Systems: Information on Type of Technology, Pipetting Technology, Certification(s) and Type of Instrument(s) by Assembly
Table 4.2 Automated Pipetting Systems: Information on Pipetting Head Option(s), Weight of Automated Pipetting System (in Kg), Compatible Labware and Application Area(s)
Table 4.3 Automated Pipetting Systems: Information on Application(s), Additional Feature(s) and End User(s)
Table 4.4 Automated Pipetting System Providers: Information on Year of Establishment, Employee Count, Company Size, Location and Region of Headquarters
Table 6.1 Automated Pipetting System Manufacturers: List of Companies Profiled
Table 6.2 Beckman Coulter Life Sciences: Company Snapshot
Table 6.3 Beckman Coulter Life Sciences: Echo 525
Table 6.4 Beckman Coulter Life Sciences: Echo 550
Table 6.5 Beckman Coulter Life Sciences: Echo 650
Table 6.6 Beckman Coulter Life Sciences: Echo 655
Table 6.7 Beckman Coulter Life Sciences: Biomek 3000
Table 6.8 Beckman Coulter Life Sciences: Biomek i5
Table 6.9 Beckman Coulter Life Sciences: Biomek i7
Table 6.10 Beckman Coulter Life Sciences: Biomek NGeniuS
Table 6.11 Beckman Coulter Life Sciences: Sagian Multipette Automated Liquid Handler
Table 6.12 Beckman Coulter Life Sciences: Biomek 4000
Table 6.13 Beckman Coulter Life Sciences: Recent Developments and Future Outlook
Table 6.14 Eppendorf: Company Snapshot
Table 6.15 Eppendorf: epMotion 5075v
Table 6.16 Eppendorf: epMotion 5075t
Table 6.17 Eppendorf: epMotion 5075l
Table 6.18 Eppendorf: epMotion 5075m
Table 6.19 Eppendorf: epMotion 5075vt
Table 6.20 Eppendorf: epMotion 5075MC
Table 6.21 Eppendorf: epMotion 5075TMX
Table 6.22 Eppendorf: epMotion 5075VAC
Table 6.23 Eppendorf: epMotion 5075LH
Table 6.24 Eppendorf: epMotion 5073t NGS solution
Table 6.25 Eppendorf: epMotion 96/96xl
Table 6.26 Eppendorf: epMotion 5070
Table 6.27 Eppendorf: Recent Developments and Future Outlook
Table 6.28 Hamilton Robotics: Company Snapshot
Table 6.29 Hamilton Robotics: Microlab STAR
Table 6.30 Hamilton Robotics: Microlab VANTAGE
Table 6.31 Hamilton Robotics: NIMBUS384
Table 6.32 Hamilton Robotics: NIMBUS4
Table 6.33 Hamilton Robotics: NIMBUS96
Table 6.34 Hamilton Robotics: Recent Developments and Future Outlook
Table 6.35 MyGenostics: Company Snapshot
Table 6.36 MyGenostics: MGS-96
Table 6.37 MyGenostics: MGN-H200/H1000
Table 6.38 MyGenostics: MGN-SIRO-4000
Table 6.39 MyGenostics: SIRO-3000
Table 7.1 Automated Microplate Washers: Information on Type of Instrument(s) by Assembly and Compatible Microplate(s)
Table 7.2 Automated Microplate Washers: Information on Weight of Automated Microplate Washer (in Kg), Compatible Software and Compatible Labware
Table 7.3 Automated Microplate Washers: Information on Application Area(s), Application(s) and End User(s)
Table 7.4 Automated Microplate Washer Providers: Information on Year of Establishment, Employee Count, Company Size, Location and Region of Headquarters
Table 9.1 Automated Microplate Washer Manufacturers: List of Companies Profiled
Table 9.2 Agilent Technologies: Company Snapshot
Table 9.3 Agilent Technologies: BioTek ELX405s
Table 9.4 Agilent Technologies: BioTek ELx405 Select
Table 9.5 Agilent Technologies: ELx405 HT
Table 9.6 Agilent Technologies: ELx405 Magna
Table 9.7 Agilent Technologies: Biotek 405TS
Table 9.8 Agilent Technologies: BioTek 50 TS
Table 9.9 Agilent Technologies: EL406 Microplate Washer Dispenser
Table 9.10 Agilent Technologies: 405 LS
Table 9.11 Agilent Technologies: Recent Developments and Future Outlook
Table 9.12 Tecan: Company Snapshot
Table 9.13 Tecan: HydroFlex
Table 9.14 Tecan: 96 PW
Table 9.15 Tecan: HydroFlex Plus
Table 9.16 Tecan: HydroSpeed
Table 9.17 Tecan: Recent Developments and Future Outlook
Table 9.18 Thermo Fisher Scientific: Company Snapshot
Table 9.19 Thermo Fisher Scientific: Wellwash Versa
Table 9.20 Thermo Fisher Scientific: Wellwash
Table 9.21 Thermo Fisher Scientific: accuWash
Table 9.22 Thermo Fisher Scientific: accuWash Versa
Table 9.23 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 10.1 Automated liquid Handling Systems: List of Partnerships and Collaborations
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top Five CPC Symbols
Table 11.3 Patent Analysis: Top Seven CPC Codes
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 15.1 Automated Pipetting Systems: Distribution by Type of Technology
Table 15.2 Automated Pipetting Systems: Distribution by Pipetting Technology
Table 15.3 Automated Pipetting Systems: Distribution by Certification(s)
Table 15.4 Automated Pipetting Systems: Distribution by Type of Instrument(s) by Assembly
Table 15.5 Automated Pipetting Systems: Distribution by Pipetting Head Option(s)
Table 15.6 Automated Pipetting Systems: Distribution by Weight of Automated Pipetting Systems (in Kg)
Table 15.7 Automated Pipetting Systems: Distribution by Compatible Labware
Table 15.8 Automated Pipetting Systems: Distribution by Application Area(s)
Table 15.9 Automated Pipetting Systems: Distribution by Application(s)
Table 15.10 Automated Pipetting Systems: Distribution by Additional Feature(s)
Table 15.11 Automated Pipetting Systems: Distribution by End User(s)
Table 15.12 Automated Pipetting System Providers: Distribution by Year of Establishment
Table 15.13 Automated Pipetting System Providers: Distribution by Company Size
Table 15.14 Automated Pipetting System Providers: Distribution by Location of Headquarters (Region-wise)
Table 15.15 Automated Pipetting System Providers: Distribution by Company Size and Location of Headquarters (Region-wise)
Table 15.16 Automated Pipetting System Providers: Distribution by Location of Headquarters (Country-wise)
Table 15.17 Most Active Players: Distribution by Number of Automated Pipetting Systems Manufactured
Table 15.18 Beckman Coulter Life Sciences: Annual Revenues, Since 2018 (USD Billion)
Table 15.19 Eppendorf: Annual Revenues, Since 2018 (USD Billion)
Table 15.20 Automated Microplate Washers: Distribution by Type of Instrument(s) by Assembly
Table 15.21 Automated Microplate Washers: Distribution by Compatible Microplate(s)
Table 15.22 Automated Microplate Washers: Distribution by Weight of Automated Microplate Washer (in Kg)
Table 15.23 Automated Microplate Washers: Distribution by Compatible Labware
Table 15.24 Automated Microplate Washers: Distribution by Application Area(s)
Table 15.25 Automated Microplate Washers: Distribution by Application(s)
Table 15.26 Automated Microplate Washers: Distribution by End User(s)
Table 15.27 Automated Microplate Washer Providers: Distribution by Year of Establishment
Table 15.28 Automated Microplate Washer Providers: Distribution by Company Size
Table 15.29 Automated Microplate Washer Providers: Distribution by Location of Headquarters (Region-wise)
Table 15.30 Automated Microplate Washer Providers: Distribution by Company Size and Location of Headquarters (Region-wise)
Table 15.31 Automated Microplate Washer Providers: Distribution by Location of Headquarters (Country-wise)
Table 15.32 Most Active Players: Distribution by Number of Compatible Software
Table 15.33 Most Active Players: Distribution by Number of Automated Microplate Washers Manufactured
Table 15.34 Agilent Technologies: Annual Revenues, Since 2018 (USD Billion)
Table 15.35 Tecan: Annual Revenues, Since 2018 (CHF Million)
Table 15.36 Thermo Fisher Scientific: Annual Revenues, Since 2018 (USD Billion)
Table 15.37 Partnerships and Collaborations: Distribution by Year of Partnership, Since 2018
Table 15.38 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.39 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2018
Table 15.40 Partnerships and Collaborations: Distribution by Type of Automated Liquid Handling System(s)
Table 15.41 Partnerships and Collaborations: Distribution by Product and Type of Partnership
Table 15.42 Most Popular Products: Distribution by Number of Partnerships
Table 15.43 Most Active Players: Distribution by Type of Partnership
Table 15.44 Partnerships and Collaborations: Local and International Agreements
Table 15.45 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 15.46 Patent Analysis: Distribution by Type of Patent
Table 15.47 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2017
Table 15.48 Patent Analysis: Year-wise Distribution by Granted Patents and Patent Applications, Since 2017
Table 15.49 Patent Analysis: Distribution by Geography
Table 15.50 Patent Analysis: Distribution by CPC Sections
Table 15.51 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Since 2017
Table 15.52 Leading Industry Players: Distribution by Number of Patents
Table 15.53 Leading Non-Industry Players: Distribution by Number of Patents
Table 15.54 Leading Individual Assignees: Distribution by Number of Patents
Table 15.55 Patent Analysis: Distribution by Patent Age
Table 15.56 Automated Liquid Handling Systems: Patent Valuation Analysis
Table 15.57 Global Automated Liquid Handling Systems Market, Till 2035
Table 15.58 Automated Liquid Handling Systems Market: Distribution by Type of Automated Liquid Handling System
Table 15.59 Automated Pipetting Systems Market: Till 2035
Table 15.60 Automated Pipetting Systems Market: Distribution by Pipetting Technology
Table 15.61 Automated Pipetting Systems Market for Contact Technology: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.62 Automated Pipetting Systems Market for Air Displacement Technology: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.63 Automated Pipetting Systems Market for Piston / Positive Displacement Technology: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.64 Automated Pipetting Systems Market for Acoustic Technology: Conservative, Base and Optimistic Scenarios: Till 2035
Table 15.65 Automated Pipetting Systems Market for Free-jet Technology: Conservative, Base and Optimistic Scenarios: Till 2035
Table 15.66 Automated Pipetting Systems Market: Distribution by Modality
Table 15.67 Automated Pipetting Systems Market for Fixed Tips: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.68 Automated Pipetting Systems Market for Disposable Tips: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.69 Automated Pipetting Systems Market: Distribution by Type of Instrument
Table 15.70 Automated Pipetting Systems Market for Standalone: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.71 Automated Pipetting Systems Market for Individual Benchtop Workstation: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.72 Automated Pipetting Systems Market for Multi Instrument System: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.73 Automated Pipetting Systems Market for Others: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.74 Automated Pipetting Systems Market: Distribution by Application
Table 15.75 Automated Pipetting Systems Market for Serial Dilution: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.76 Automated Pipetting Systems Market for Plate Replication: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.77 Automated Pipetting Systems Market for PCR / qPCR Setup: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.78 Automated Pipetting Systems Market for Plate Reformatting: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.79 Automated Pipetting Systems Market for High-throughput Screening: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.80 Automated Pipetting Systems Market for Whole Genome Amplification: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.81 Automated Pipetting Systems Market for Cell Culture: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.82 Automated Pipetting Systems Market for Other Applications: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.83 Automated Pipetting Systems Market: Distribution by End User
Table 15.84 Automated Pipetting Systems Market for Biotechnology and Pharmaceutical Companies: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.85 Automated Pipetting Systems Market for Academic and Government Research Institutes: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.86 Automated Pipetting Systems Market for Hospitals and Diagnostic Centers: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.87 Automated Pipetting Systems Market for Other End Users: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.88 Automated Pipetting Systems Market: Distribution by Key Geographical Regions
Table 15.89 Automated Pipetting Systems Market in North America: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.90 Automated Pipetting Systems Market in Europe: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.91 Automated Pipetting Systems Market in Asia-Pacific: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.92 Automated Pipetting Systems Market in Middle East and North Africa: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.93 Automated Pipetting Systems Market in Latin America: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.94 Automated Microplate Washers Market: Till 2035
Table 15.95 Automated Microplate Washers Market: Distribution by Washing Technology
Table 15.96 Automated Microplate Washers Market for Ultrasonic Technology: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.97 Automated Microplate Washers Market for Acoustic Technology: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.98 Automated Microplate Washers Market for Centrifugal Technology: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.99 Automated Microplate Washers Market: Distribution by Application
Table 15.100 Automated Microplate Washers Market for ELISA: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.101 Automated Microplate Washers Market for Cell-based Assays: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.102 Automated Microplate Washers Market for Bead Washing: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.103 Automated Microplate Washers Market for Other Applications: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.104 Automated Microplate Washers Market: Distribution by End User
Table 15.105 Automated Microplate Washers Market for Biotechnology and Pharmaceutical Companies: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.106 Automated Microplate Washers Market for Academic and Government Research Institutes: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.107 Automated Microplate Washers Market for Hospitals and Diagnostic Centers: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.108 Automated Microplate Washers Market for Other End Users: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.109 Automated Microplate Washers Market: Distribution by Key Geographical Regions
Table 15.110 Automated Microplate Washers Market in North America: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.111 Automated Microplate Washers Market in Europe: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.112 Automated Microplate Washers Market in Asia-Pacific: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.113 Automated Microplate Washers Market in Middle East and North Africa: Conservative, Base and Optimistic Scenarios, Till 2035
Table 15.114 Automated Microplate Washers Market in Latin America: Conservative, Base and Optimistic Scenarios, Till 2035

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie
  • AbClon
  • Abeome
  • ABL Bio
  • Abpro
  • Acerta Pharma
  • Acrus Biosciences
  • Actinium Pharmaceuticals
  • Adaptive Biotechnologies
  • AdoRx Therapeutics
  • Aduro Biotech
  • Advaxis
  • Agenus
  • Agios Pharmaceuticals
  • Alexion Pharmaceuticals
  • Allergan
  • Alligator Bioscience
  • Alpine Immune Sciences
  • ALX Oncology
  • Amgen
  • Angel Therapeutics
  • Anvil Biosciences (The company has been acquired)
  • Apexigen
  • Apogenix
  • Aptevo Therapeutics
  • Arch Oncology
  • Arcus Biosciences
  • ArQule
  • Astellas Pharma
  • Astex Pharmaceuticals
  • AstraZeneca
  • Atridia
  • Aurigene Discovery Technologies
  • Avacta Life Sciences
  • Bach BioSciences
  • BeiGene
  • BinDeBio Group
  • BIOCAD
  • Biodextris
  • BioNTech
  • Bio-Techne
  • Black Belt Therapeutics
  • BliNK Biomedical
  • bluebird bio
  • Boehringer Ingelheim
  • Boston Medical Center
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Calithera Biosciences
  • CALIXAR
  • CASI Pharmaceuticals
  • Catalent Biologics
  • Celgene
  • Celldex Therapeutics
  • Center for Applied Medical Research
  • Centrose
  • Checkpoint Therapeutics
  • China National Biotec Group
  • CleveXel Pharma
  • Columbia University Irving Medical Center
  • Compass Therapeutics
  • Compugen
  • Corvus Pharmaceuticals
  • Crescendo Biologics
  • CStone Pharmaceuticals
  • Curis
  • D5Pharma
  • Daiichi Sankyo
  • Distributed Bio
  • DNAtrix
  • Domain Therapeutics
  • Dova Pharmaceuticals
  • Dualogics
  • Eisai
  • Eli Lilly
  • Elpiscience Biopharma
  • ELSALYS BIOTECH
  • EMulate Therapeutics
  • EpicentRx
  • FF Pharmaceuticals
  • Five Prime Therapeutics
  • Forty Seven
  • Fred Hutchinson Cancer Research Center
  • F-star
  • Gateway Biologics
  • Genentech
  • Genmab
  • Genomics Medicine Ireland
  • Genosco
  • GigaGen
  • Gilead Sciences
  • Glaxosmithkline
  • Glenmark
  • Glycotope
  • Hanmi Pharmaceutical
  • HanX Biopharmaceuticals
  • Heat Biologics
  • Hrain Biotechnology
  • Hummingbird Bioscience
  • IGM Biosciences
  • I-Mab Biopharma
  • Immatics
  • ImmuneOncia Therapeutics
  • ImmuneOnco Biopharmaceuticals
  • ImmuNext
  • Impetis Biosciences
  • Incyte
  • Inhibrx
  • Innate Pharma
  • Innovent Biologics
  • Institute for Research in Biomedicine
  • InteRNA Technologies
  • International Myeloma Foundation
  • IO Biotech
  • iOnctura
  • iTeos Therapeutics
  • Janssen Pharmaceuticals
  • Jiangxi Qingfeng Pharmaceutical
  • JN Biosciences
  • Johns Hopkins University
  • Johnson & Johnson
  • Juventas Cell Therapy
  • KAHR Medical
  • Kiniksa Pharmaceuticals
  • Kite Pharma
  • Kleo Pharmaceuticals
  • Kymab
  • Kyowa Hakko Kirin
  • Leap Therapeutics
  • LG Chem
  • LifeArc
  • Lynkcell
  • Macrocure
  • MacroGenics
  • Marino Biotechnology
  • Massachusetts General Hospital
  • MedImmune
  • Merck
  • Merus
  • Moderna
  • Molecular Partners
  • Molecular Templates
  • Momenta Pharmaceuticals
  • Morphiex
  • MorphoSys
  • Mount Sinai Innovation Partners
  • Nanjing Chia Tai Tianqing
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute of Dental and Craniofacial Research
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Neurological Disorders
  • NavarraBiomed-Biomedical Research Centre
  • Navigen
  • Neon Therapeutics
  • NewLink Genetics
  • NextCure
  • Novartis
  • Novimmune
  • Numab Therapeutics
  • Ogeda
  • OncoArendi Therapeutics
  • Oncotelic
  • Ono Pharmaceutical
  • ORIC Pharmaceuticals
  • OSE Immunotherapeutics
  • Palobiofarma
  • Pandion Therapeutics
  • Paradigm Shift Therapeutics
  • Parker Institute for Cancer Immunotherapy
  • Pascal Biosciences
  • Peloton Therapeutics
  • PeptiDream
  • PersonGen BioTherapeutics (Suzhou)
  • Pfizer
  • PharmAbcine
  • Pieris Pharmaceuticals
  • Pinze Lifetechnology
  • Potenza Therapeutics
  • PsiOxus Therapeutics
  • Roche
  • Rubius Therapeutics
  • Sanofi
  • Sanquin
  • Seattle Genetics
  • Shanghai GeneChem
  • Shattuck Labs
  • Shire
  • Sorrento Therapeutics
  • Stanford University
  • Surface Oncology
  • Sutro Biopharma
  • Swedish Orphan Biovitrum
  • Symphogen
  • Synthon International Holding
  • Syros Pharmaceuticals
  • Takeda Pharmaceutical
  • Tarus Therapeutics
  • Tempest Therapeutics
  • TESARO
  • TG Therapeutics
  • The University of Texas MD Anderson Cancer Center
  • Tottori University
  • TRACON Pharmaceuticals
  • Trellis Biosciences
  • TRIGR Therapeutics
  • Trillium Therapeutics
  • Tsinghua University
  • Union Stem Cell & Gene Engineering
  • University of California San Francisco
  • University of California, Los Angeles
  • University of California, San Diego
  • University of Minnesota
  • Vall d’Hebron Institute of Oncology
  • Valo Therapeutics
  • Viela Bio
  • ViraTherapeutics
  • Vivoryon Therapeutics
  • Washington University
  • Waterstone Hanxbio
  • Xencor
  • XOMA
  • Y-Biologics
  • Yale Cancer Center
  • Yale University
  • Y-mAbs Therapeutics
  • Yuhan Pharmaceuticals
  • Zai Lab
  • Zymeworks

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report 2026 - Product Image

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Oncology Precision Medicine Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecasts - Product Image

Oncology Precision Medicine Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecasts

  • Report
  • 468 Pages
  • Global
From
Checkpoint Inhibitor Refractory Cancer Market Report 2026 - Product Image

Checkpoint Inhibitor Refractory Cancer Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Checkpoint Inhibitors Market Report 2026 - Product Image

Checkpoint Inhibitors Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Immune Checkpoint Inhibitors for Cancer Market - Global Forecast 2026-2032 - Product Image

Immune Checkpoint Inhibitors for Cancer Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.